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factor that signiﬁcantly correlated with the risk of RILT (P = 0.035, 
OR = 2.354). If patients were grouped based on high or low TGF-β1 
ratio (during RT/pre-RT), 13 out of the 29 patients with a TGF-β1 ratio 
higher than the median level of 0.8 developed RILT, while only 5 out 
of the 35 patients with low TGF-β1 ratios developed RILT (P = 0.007). 
No signiﬁcant correlation was seen between TGF-β1 ratio and MLD or 
between TGF-β1 ratio and the decline in DLCO
Conclusion: An increase in plasma TGF-β1 level during RT may be 
predictive of RILT. The potential use of TGF-β1 levels during RT to 
adapt RT delivery deserves further study.
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Objective: To study the relationship between level of plasma transform 
growth factor bata (TGF-beta), interleukin (IL-6), angiotensin-convert-
ing enzyme (ACE) and physical parameters (V10, V15, V20, MLD) 
and radiation pneumonitis (RP). 
Methods: The records of all patients with lung cancer treated with 
radiotherapy (RT) with curative intent from February 2004 to August 
2005. A total of 67 patients were identiﬁed who met the following 
inclusion criteria: (1) newly diagnosed lung cancer of any histology 
treated with RT± chemotherapy with curative intent; (2) a Karnofsky 
performance status >70; (3) expected survival >6 months; (4) follow-
up time more than 6 months; (5) no pneumonectomy. Blood samples 
were collected and measured with enzyme-linked immunosorbent assay 
(ELISA). TGF-beta, IL-6 and ACE measurements obtained before RT 
(Pre-RT) and when RT dose reached 40-50Gy (during-RT). Fifty-eight 
patients were treated with computed tomography based 3-dimensional 
planning and had dose-volume histogram data available. The endpoint 
of the study was the development of ≥ grade 2 RP (NCI [National Can-
cer Institute] common toxicity criteria 3.0). 
Results: The Median follow-up time of the alive patients is 22.6 
months. The incidence of ≥ grade 2 RP for all 67 patients was 25.4%. 
Between the RP and non-RP group, there was no difference in Pre- or 
during- RT level of TGF-beta, IL-6. We observed ACE level was lower 
in RP group than in the non-RP group, both pre-RT and during-RT 
(p=0.033 and p=0.004). Fifty-eight patients received 3-dimensional 
conformal RT (3DCRT). In RP group, patients are received higher all 
lung V10, contra lateral MLD, contra lateral V10, contra lateral V15, 
contra lateral V20 (44% vs 39%, 1931cGy vs 990cGy, 52% vs 35%, 
48% vs 27%, 37% vs 10% P< 0.05). The subgroup of 54 patients 
treated with 3DCRT and the data of ACE level were available, were 
divided into groups according to their plasma ACE median level and 
whether their V10 level was above or below the median of 40%; Group 
I (n=13), with ACE > 506ng/ml and V10 ≤ 40%; Group II (n=30), with 
ACE > 506ng/ml and V10 > 40%; ACE ≤ 506ng/ml and V10 ≤ 40%; 
Group III (n=12), with ACE ≤506ng/ml and V10 > 40%. A signiﬁcant 
different was found in the incidence of RP among these three groups 
(0%, 26.7%, 50.0% p=0.008) 
Conclusions: (1) A lower plasma ACE level during-RT is an indepen-
dent risk factor for RP; (2) The combination of plasma ACE level and 
V10 appears to facilitate stratiﬁcation of patients into three groups. 
Thus, combining both physical and biologic risk factors may allow for 
better identiﬁcation of patients at risk for the development of symptom-
atic radiation-induced lung pneumonitis.
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Background: Knowledge of changes in volume and motion of either 
tumor or involved lymph nodes during a course of radiotherapy is nec-
essary to improve the treatment (adaptive radiotherapy). These changes 
for the primary tumor were already reported (Bosmans et al, Int J 
Radiat Oncol Biol Phys, 2006). The purpose of this study is describing 
the time trends in nodal CT volume and nodal motion, for patients with 
locally advanced non-small cell lung cancer.
Methods: Eleven patients, with a total of 21 nodes, from a prospective 
clinical trial underwent CT-PET scans prior to treatment, which was 
repeated in the ﬁrst and second week following the start of radiothera-
py. For 20 nodes, the motion could be measured based on a respiration 
correlated CT (RCCT) scan. Moreover, repeated RCCT scans were 
available for 11 nodes to evaluate the change in motion. Patients were 
treated with an accelerated fractionation schedule, 1.8 Gy BID, with 
a total tumor dose depending on pre-set dose constraints for the lungs 
and the spinal cord. 
Results: A heterogeneity of nodal volume changes was observed at all 
time points similar to the tumor volume changes. In some patients the 
nodal volume increased > 50% (4/21) in others the volume decreased 
> 50% (1/21) but for the majority of nodal areas (16/21) the volume 
only changed slightly (< 50%). The initial absolute nodal volume was 
4.5 cc ± 4.3 cc, therefore large volume changes were observed and the 
delineation of small volumes is sensitive to intra-observer variability. 
On average the nodal volume did not change signiﬁcantly (4.5, 4.9 
and 4.3 cc prior to treatment, 1 and 2 weeks after the start of treatment 
respectively). The 3D vector motion, which is the quadratic sum of the 
